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Abstract
Background: Nasal high-flow oxygen therapy (HFOT) is a novel treatment option for patients suffering from acute
or chronic respiratory failure. Aim of our study was to compare safety and efficacy of HFOT with those of
conventional oxygen treatment (COT) in normo- and hypercapnic COPD patients.
Methods: A single cohort of 77 clinically stable hypoxemic patients with an indication for long-term oxygen
treatment (LTOT) with or without hypercapnia successively received COT and HFOT for 60 min each, including
oxygen adaption and separated by a 30 min washout phase.
Results: HFOT was well-tolerated in all patients. A significant decrease in PaCO2 was observed during oxygen
adaption of HFOT, and increased PaO2 coincided with significantly increased SpO2 and decreased AaDO2 during
both treatment phases. Even at a flow rate of 15 L/min, oxygen requirement delivered as air mixture by HFOT
tended to be lower than that of COT (2.2 L/min). Not only was no increase in static or dynamic lung volumes
observed during HFOT, but even was a significant reduction of residual lung volume measured in 36 patients (28%).
Conclusions: Thus, short-term use of HFOT is safe in both normocapnic and hypercapnic COPD patients. Lower oxygen
levels were effective in correcting hypoxemic respiratory failure and reducing hypercapnia, leading to a reduced amount
of oxygen consumption. Long-term studies are needed to assess safety, tolerability, and clinical efficacy of HFOT.
Trial registration: ClinicalTrials.gov NCT01686893 13.09.2012 retrospectively registered (STIT-1) and NCT01693146 14.09.
2012 retrospectively registered (STIT-2). Studies were approved by the local ethics committee (Ethikkommission der
Medizinischen Universität Innsbruck, Studienkennzahl UN3547, Sitzungsnummer 274/4.19).
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Summary
Short-term nasal highflow oxygen therapy (HFOT) is
safe and efficacious in normocapnic and hypercapnic
COPD patients.
Background
Nasal high-flow oxygen therapy (HFOT) is a novel non-
invasive alternative to conventional oxygen treatment
(COT) and an alternative to non-invasive ventilation in
selected patients. It is based on the transnasal applica-
tion of a preheated and moistened air-oxygen
composition at high flow rates [1, 2]. Besides pharma-
ceutical treatment options, long-term oxygen treatment
(LTOT) and non-invasive ventilation have become a
main emphasis in the therapy of respiratory insufficiency
including chronic obstructive pulmonary disease
(COPD), sleep apnoea, pulmonary oedema, and other
conditions [3]. The prevalence of COPD worldwide is
between 9 and 10% in people over the age of 40, with the
incidence significantly varying between countries, i.e. ran-
ging from 0.2% in Japan to 37% in the USA. Men are more
often affected than women [4, 5]. According to the WHO,
COPD is the fourth leading cause of death and is supposed
to become the third leading cause by 2020 [6]. COPD is
marked by an airflow limitation with persistent and pro-
gressive courses of breathlessness, frequently associated
with chronic productive cough and chest tightness [7].
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As a conventional treatment option, typically applied
in case of persistent hypoxaemia (PaO2 < 55 mmHg or
<60 mmHg upon signs of right heart failure or polycy-
thaemia), LTOT via a nasal cannula or oxygen mask has
been successfully performed for decades. So far, LTOT
represents the only life-extending therapy in severe lung
disease [8, 9]. However, long-term modes of treatment
remain inapplicable in patients with restricting factors
and usually lead to limitations in the patients’ mobility
and quality of life [10]. Recent studies illustrated further
limitations of conventional LTOT, becoming particularly
evident in cases of exacerbations or at later stages of the
disease [11]. As an optional way of treatment that re-
cently moved into focus, HFOT has been investigated,
and specific devices such as TNI®20 oxy (TNI medical
AG, Würzburg, Germany) have been developed [12]. For
HFOT, humidification and preheating of the applied gas
offers a suitable precondition to achieve high flow rates
and prevent airway dehydration. An obvious advantage
of nasal application over respiratory masks lies in im-
proved ways of daily activity, free ability to communi-
cate, and higher levels of compliance [13].
Successful applications of HFOT in the past included
paediatric treatments, in which intubation or continuous
positive airway pressure could be prevented, and the
treatment of respiratory distress syndrome [14]. Simi-
larly, treatment approaches in premature infants have
been shown to exert beneficial effects in cases of apnoea
and other indications in children, such as infectious
bronchiolitis, pneumonia, and congestive heart failure
[14, 15]. A number of recent clinical investigations pro-
vided a strong input to the HFOT strategy and under-
lined the benefits of various HFOT applications [16–20].
So far, however, clear information is limited on
whether HFOT is reliably beneficial for the broader
treatment of respiratory insufficiencies and may provide
advantages over conventional forms of therapy. In this
study, the question was addressed whether HFOT pro-
vides the same safety and efficacy as COT in the treat-
ment of hypoxaemic COPD patients with both normo-
or hypercapnia. Primary and secondary endpoints of the
study were set as changes in the partial oxygen and car-
bon dioxide pressure (PaO2, PaCO2), the alveolar to ar-
terial oxygen pressure difference (AaDO2), and
peripheral oxygen saturation (SpO2) at a defined oxygen
flow rate, as well as safety of HFOT as assessed by lung
volume changes. Thus, our study verifies for the first
time that HFOT is safe and efficacious in COPD patients
with or without hypercapnia.
Methods
Study population
The study population comprised a single cohort of 77
COPD patients, who were already treated by
conventional LTOT and stabilized, then awaiting a po-
tential inclusion into the subsequent HFOT studies
STIT-1 and -2 (Short Time TNI Treatment). Inclusion
criteria of the STIT-1 study on normocapnic COPD pa-
tients were defined by the indication for LTOT (PaO2 <
55 mmHg or <60 mmHg upon signs of right heart fail-
ure or polycythaemia), age 30–80 years, and functional
class COPD GOLD IV (as defined by FEV1/FVC < 70%,
post-bronchodilator forced expiratory volume in 1 s
[FEV1] < 30% pred., or <50% pred. With LTOT indica-
tion). Two groups were defined by the post-
bronchodilator FEV1, with group 1 corresponding to
30% pred. ≤ FEV1 < 50% pred. And group 2 correspond-
ing to FEV1 < 30% pred. [21]. The number of patients
announced/analysed was 50/50 in STIT-1. Inclusion cri-
teria of the STIT-2 study on hypercapnic COPD patients
were an indication for LTOT (see above), PaCO2 >
45 mmHg at rest without oxygen supplementation, age
30–85 years, and functional class COPD GOLD IV (see
above). The number of patients announced/analysed was
20/27. Exclusion criteria in both studies were clinical in-
stability, lack of option for testing lung function, exacer-
bation within the last 14 days, serious concomitant
diseases, severe anaemia (haemoglobin <8.5 g/L), miss-
ing consent or participation in any other ongoing study.
Any oral or inhaled medication approved for COPD
therapy was allowed. Studies STIT-1 and STIT-2 lasted
from 02/08 and 11/11 (first patient first visit) to 12/11
and 06/12, respectively. Both studies were extended to
06/14. Studies were registered at ClinicalTrials.gov
NCT01686893 (STIT-1 [22]) and NCT01693146 (STIT-
2 [23]) and approved by the local ethics committee.
Study design
This prospective study was directed to a single cohort of
patients participating in sub study STIT-1 or STIT-2.
During the screening visit, arranged 2 weeks prior to
start of each sub study, informed consent was obtained.
Every patient was informed about the new method of
HFOT and its possible effects for COPD patients, fur-
thermore about the course of the study and the extra in-
vestigations during the study. The patient’s history as
well as demographic and clinical parameters were
assessed. Patients (n = 77) received first COT, which was
followed by HFOT, each for 60 min including initial oxy-
gen adaption (see below). For COT, oxygen was applied
using the hospital’s standard oxygen system and stand-
ard nasal prongs, and TNI®20 oxy (TNI medical AG,
Würzburg, Germany) was employed as HFOT device.
Both treatment phases were separated by a 30 min
washout phase in a sitting position, without oxygen (see
below). Physical examinations, analysis of vital signs, and
blood gas analysis were performed repeatedly as follows:
at the screening visit, at baseline, during both oxygen
Vogelsinger et al. BMC Pulmonary Medicine  (2017) 17:143 Page 2 of 8
adaption phases, after the 30 min washout phase, and
after COT and HFOT treatment. Bodyplethysmography,
spirometry and DLCO (diffusing capacity of lung carbon
monoxide) measurement were performed at the screen-
ing visit, at baseline and after COT and HFOT. Primary
endpoint was the change in PaO2 in the arterialised ca-
pillary blood (blood gas analysis) at a defined oxygen
flow rate (L/min). Secondary endpoints were changes in
SpO2, PaCO2 and AaDO2 in the arterialised capillary
blood (blood gas analysis) at a defined oxygen flow rate
(L/min), and safety of the device in normocapnic (STIT-
1) and hypercapnic COPD patients (STIT-2), as defined
as no increase in the residual volume (RV) and the total
lung capacity (TLC) > 15% of the mean actual value.
After treatment, patient satisfaction was assessed in
non-standardized surveys.
Oxygen adaptation of COT and HFOT
Oxygen adaption of both COT and HFOT followed the
same standard protocol. Nasal oxygen insufflation with
conventional oxygen started at 0.5 L/min and was in-
creased in steps of 0.5 to 1 L/min until PaO2 was
>60 mmHg or PaO2 increased by ≥10 mmHg as com-
pared to the initial value. After successful adaptation, pa-
tients received nasal oxygen insufflation at the
established flow rate for the remaining duration of the
hour to be completed. Blood gas analysis, performed
after 10 min at a defined flow rate, was mandatory at the
beginning of oxygen adaptation and was completed 1 h
thereafter. Oxygen flow rate could be increased without
blood gas analysis if a SpO2 > 90% was not reached. A
30 min washout phase at rest, in a sitting position, with-
out oxygen then followed COT. During the washout
phase, PaO2 should decline to initial levels (± 2 mmHg).
Adaptation to the HFOT phase was achieved by titration
starting from room air conditions (oxygen admixture
0 L/min) towards a nasal oxygen insufflation of 15 L/
min, under oxygen admixture steps of 0.5 L/min until
reaching a value of PaO2 > 60 mmHg or an increase of
≥10 mmHg (in contrast, adaptation to COT started at
0.5 L/min). All subsequent steps followed the protocol
described above.
Procedures
For clinical examinations, vital signs (blood pressure and
heart rate) were measured at the beginning and at the
end of each point of the study. Blood gases were taken
from the hyperaemic ear lobe (anointed with Finalgon
[Boehringer-Ingelheim] to increase perfusion) with a
single-use system. Hyperaemisation leads to arterialisa-
tion of capillary blood, thus the arterial values (PaO2,
PaCO2) are reflected adequately. The collected blood
samples were analysed with a routinely used and daily
calibrated blood gas analysis device within 2 min after
puncture. The bodyplethysmography, spirometry and
DLCO measurements comprised the assessment of dy-
namic and static lung parameters as follows: (i) dynamic
volumes such as FEV1% (forced expiratory volume in 1
s), RAW (airway resistance) and (ii) static volumes such
as ERV (expiratory reserve volume), IC (inspiratory cap-
acity), VC (vital capacity, Vcex and Vcin), RV (residual
volume), and TLC (total lung capacity). Static and dy-
namic lung volumes were recorded with the MasterSc-
reen Body© (CareFusion, Hoechberg, Germany) and
Pneumotach© (Jaeger, Würzburg, Germany) providing
flow measurements in a range up to 20 L/s and an ac-
curacy of ±2%. Volume determination was performed by
digital integration within a range of ±20 L and an accur-
acy of ±3% or ±50 ml. Pressure measurements were
piezoresistive with an accuracy of ±2%.
Statistic evaluation
For statistical analyses, continuous data were described
in terms of number, minimum, maximum, mean value,
median, and standard deviation. Discrete data sets were
described in terms of number and percentage. To inves-
tigate differences in oxygen quantities, a paired sample
test was used. As the central issue of statistical evalu-
ation, the oxygen flow required to achieve a PaO2 of
>60 mmHg or an increase by at least 10 mmHg when
using COT were contrasted to HFOT. The software
used was SPSS Statistics 15.0. All values are given as
mean ± SD, and data were considered as significant by
the Student’s t-test when p < 0.001.
Results
Patient characteristics
Characteristics of the study population, based on defined
inclusion and exclusion criteria, is depicted in Fig. 1. Pa-
tients of both sub studies were, on average, 66.2 ±
8.5 years old (range 47–84 years), and males were pre-
dominant (74%). Their mean FEV1 was 31.0 ± 11.4% of
the predicted value, and patients were classified into
FEV1 30–50% pred. (n = 38) and FEV1 < 30% pred. (n =
39). At screening visit, mean (± SD) PaO2 and PaCO2
values were 49.6 ± 6.2 mmHg and 43.2 ± 6.3 mmHg, re-
spectively, with a SpO2 at 91 ± 2%. Mean LTOT oxygen
flow rates (± SD) of 2.2 ± 1.6 L/min (anamnestic) indi-
cated that patients were clinically stable (table 1).
Blood gas analysis and oxygen requirement
Patients (n = 77) successively received COT and HFOT,
each for 60 min and separated by a 30 min washout phase
(Fig. 2). Blood gas and vital signs were analysed at the
screening visit, at baseline, after oxygen adaption (PaO2 >
60 mmHg or increased by ≥10 mmHg when compared to
baseline), and at the end of each treatment. Bodyplethys-
mography, spirometry and DLCO measurements were
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performed at the screening visit, at baseline, and at the
end of each 1-h treatment session.
The starting mean baseline PaO2 of 49.6 ± 6.2 mmHg
and 48.7 ± 5.8 mmHg increased to 63.8 ± 5.1 mmHg and
61.4 ± 6.0 mmHg during oxygen adaption of COT and
HFOT, respectively, and remained constant during the
remaining hour of treatment (Fig. 3).
After both treatments, SpO2 baseline levels were sig-
nificantly increased (p < 0.0001; data not shown). HFOT
reduced PaCO2 levels already during oxygen adaptation
(−2.36 mmHg, p < 0.038) which remained on a lower
level until the end of treatment (−2.11 mmHg, p <
0.077). In contrast, PaCO2 slightly increased during
COT (Fig. 3), and PaCO2 differences between COT and
HFOT were significant after both oxygen adaptation and
1-h treatment session (p < 0.0001). Under these HFOT
conditions (constant flow rate of 15 L/min), overall oxy-
gen requirement of HFOT was lower than that of COT
in normocapnic (1.87 ± 1.57 L/min vs. 2.07 ± 1.65 L/min)
and hypercapnic (2.09 ± 1.14 L/min vs. 2.15 ± 1.37 L/
min,) COPD patients.
Figure 4 shows the combined data for both normocap-
nic and hypercapnic patients, demonstrating the reduced
amount of oxygen required to achieve comparable oxy-
genation during HFOT (1.95 ± 1.45 L/min vs. 2.1 ±
1.57 L/min). A FiO2 of 31.11 ± 7.63% during HFOT was
documented to achieve required patients´ oxygenation.
Of note, in some cases (n = 6), in which the patient’s
need of oxygen remained moderately low, room air con-
centrations were sufficient for HFOT without any oxy-
gen admixture. In addition, AaDO2 declined from 50.33
to 35.87 mmHg under COT and from 51.91 to
39.49 mmHg under HFOT, respectively, with each de-
crease being significant (p < 0.0001).
Safety
No alterations of lung function parameters were de-
tected during the study period (Fig. 5). Interestingly, in
28% of patients (36/77), the RV was significantly lower
after HFOT than that after COT (4.17 ± 1.03 L vs. 4.68
± 1.53 L; p < 0.0001). In addition, there were no signifi-
cant differences in DLCO (3.96 ± 1.59 mmol/min/kPa vs.
3.89 ± 1.51 mmol/min/kPa) and RAW after both treat-
ment regimens (0.83 ± 0.84 kPa/L/s vs. 0.87 ± 0.57 kPa/
L/s). No adverse events and no significant alterations in
blood pressure or cardiac frequency were noted. HFOT
was well tolerated by all 77 patients.
Discussion
In this study, we analysed HFOT as a novel treatment
option for chronic hypoxaemic respiratory failure in
both normocapnic and hypercapnic COPD patients, and
compared it to the classical mode of COT concerning ef-
ficacy of oxygenation and safety. The main results of the
study were that (i) HFOT was well-tolerated by all 77
patients, (ii) the level of oxygen requirement (FiO2) was
generally lower under HFOT, (iii) hypercapnia was sig-
nificantly reduced under HFOT, and (iv) HFOT was safe
as no increase in residual volumes or any alteration of
Fig. 1 Enrollment of normocapnic and hypercapnic COPD patients in
STIT-1 and STIT-2. 200 patients with COPD GOLD IV were screened for
study inclusion. The final study population comprised a single cohort
of 77 stable COPD patients, who were already treated by conventional
long term oxygen treatment (LTOT), then awaiting a potential inclusion
into the subsequent HFOT studies STIT-1 and -2 (Short Time
TNI Treatment)
Table 1 Patient characteristics and lung function at screening
visit
STIT-1 STIT-2 STIT-1 + 2
Patient demographics
Sample size (n) 50 27 77
Sex (male/female) 42/8 15/12 57/20
Age, years (mean ± SD) 67.2 ± 8.5 64.4 ± 8.2 66.2 ± 8.5
FEV1 group: 30–50% (n) 31 7 38
FEV1 group: < 30% (n) 19 20 39
Lung function
pred. FEV1, % (mean ± SD) 34.5 ± 11.2 24.9 ± 9.2 31.0 ± 11.4
LTOT, O2 L/min (mean ± SD) 2.2 ± 1.7 2.4 ± 1.4 2.2 ± 1.6
PaO2, mmHg (mean ± SD) 51.0 ± 6.1 47.0 ± 5.6 49.6 ± 6.2
PaCO2, mmHg (mean ± SD) 40.0 ± 4.1 49.1 ± 5.4 43.2 ± 6.3
SpO2 (%) 91 ± 2 89 ± 3 91 ± 2
FEV1: forced expiratory volume in 1 s; LTOT: long term oxygen therapy
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total lung volumes occurred. We therefore conclude that
HFOT offers therapeutic benefits for both normocapnic
and hypercapnic COPD patients as a new procedure for
the future. As compared to standard therapy (COT), lower
levels of oxygen were effective in correcting hypoxaemic
respiratory failure and reducing hypercapnia, ultimately
leading to an economization of oxygen consumption.
To date, COT has been the most frequently used
oxygenation assistance (LTOT) in the therapy of se-
vere COPD that was shown to improve survival. With
HFOT, a completely new method has recently been
introduced. However, data on safety in severely ill
COPD patients with hypoxaemia, hyperinflation and
consequently hypercapnia are still missing. Therefore,
the aim of our study was to examine general parame-
ters of reliability and usefulness in the treatment of
severe COPD. Under HFOT, PaO2 substantially in-
creased and remained constant throughout the period
of treatment. Likewise, SpO2 was significantly in-
creased, while PaCO2 levels already declined during
oxygen adaptation of HFOT. Furthermore, also
AaDO2 was significantly reduced by both COT and
HFOT.
Regarding oxygenation, HFOT seems to be superior to
COT. In our experiments lower FiO2 rates were neces-
sary to achieve the predefined PaO2 in our patients. Util-
izing COT 100% of oxygen is inspired. Wettstein et al.
reported that using COT FiO2 increases with increasing
flow rates. COT was delivered at a mean flow rate of 2.2
± 1.6 L/min. In the data published by Wettstein and col-
leagues a pharyngeal FiO2 of 0.30 to 0.38 can be mea-
sured at a COT flow rate of 2 L/min. However, also FiO2
of 31.11 ± 7.63% during HFOT was measured with
higher flow rates and applying an air/oxygen mixture.
Higher flow rates might even further reduce oxygen de-
mand in these patients, which might be of socio-
economical relevance.
Thus, one of the essential findings was the clear reduc-
tion of PaCO2 during HFOT compared to COT as veri-
fied in both subgroups of the patient collective. As a
potential reason, an improved washout effect of the
nasopharyngeal dead space or, alternatively, an increase
Fig. 2 Study procedures and measurements. Stable patients with COPD GOLD IV (n = 77) successively received conventional oxygen therapy
(COT) and nasal high-flow oxygen therapy (HFOT), each for 60 min and separated by a 30 min washout phase. Blood gas and vital signs were
analysed at the screening visit, at baseline, after oxygen adaption (PaO2 > 60 mmHg or increased by ≥10 mmHg when compared to baseline),
and at the end of each treatment. Bodyplethysmography, spirometry and DLCO measurements were performed at the screening visit, at baseline,
and at the end of each 1-h treatment session
Fig. 3 Mean blood gas values during conventional oxygen therapy (COT) and nasal high-flow oxygen therapy (HFOT). Blood samples (n = 77)
were subjected to measurements of PaCO2 (dotted line) and PaO2 (solid line) at baseline (1), after 10–60 min of oxygen adaptation until reaching
a value of PaO2 > 60 mmHg or an increase of ≥10 mmHg (2), and at the end of the 60-min treatment period [including adaption] (3)
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in pharyngeal pressure due to the elevated flow rate
under HFOT appears plausible [14]. Hereby, the de-
crease of PaCO2 in hypercapnic patients needs to be
stressed as a quality of particular importance since it
lowers the risk of respiratory arrest, especially in cases of
acute exacerbation. This finding is supported by previ-
ous studies showing a significant decline in PaCO2 with
HFOT [12, 24]. Frizzoli et al. [24] observed decreasing
PaCO2 with rising flow and explained the effect with im-
proved wash out efficiency of the nasopharyngeal dead
Fig. 4 Oxygen requirement during nasal high-flow oxygen therapy (HFOT). Mean oxygen consumption during conventional oxygen therapy
(COT) and HFOT was recorded in 77 patients with stable COPD GOLD IV(combining 50 normocapnic and 27 hypercapnic COPD patients), as
assessed by blood gas analysis
Fig. 5 Determination of lung function parameters under nasal high-flow oxygen therapy (HFOT) in 77 stable COPD patients. Dynamic and static
lung parameters after both conventional oxygen therapy (COT; white bars) and HFOT (grey bars) were expressed in percent of the predicted
value: FEV1 (forced expiratory volume in 1 s), ERV (expiratory reserve volume), IC (inspiratory capacity), VC (vital capacity), RV (residual volume),
and TLC (total lung capacity)
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space. According to these results, PaCO2 should not be
affected by tracheal pressure but solely by higher flow
rates. This possibility, however, was contradicted by Mc
Ginley et al. [13], explaining this HFOT-based effect by
an increase in pharyngeal pressure. In essence, these
findings point to the hypothesis of an overall improve-
ment in oxygenation by HFOT, which has not been de-
scribed in the literature until now [1, 3, 25].
As far as safety parameters are concerned, it should be
stressed that during HFOT neither deterioration of lung
volumes, nor significant differences in DLCO, RAW levels
or other adverse events were noted. The high level of pa-
tient satisfaction was deemed as a further success of the
use of HFOT in the cohort. All patients rated HFOT as
‘pleasant’, which is compatible with earlier studies stressing
the improved comfort as based on low levels of dyspnoea
and mouth dryness as well as a lack of restrictions in food
ingestion or speaking [26]. This positive general evaluation
was also supported by other observations, such as a reduc-
tion of dyspnoea attributed to a correction of hypoxaemia
and a reduction of the respiratory rate and the humidifica-
tion providing a higher secretion clearance and an im-
proved mucociliary function in the airways [26].
Recently, the benefit of HFOT applications has been
demonstrated by several reports, underlining that HFOT
is well tolerated by patients with mild to moderate hyp-
oxic respiratory failure [19]. Frat et al. [16] demonstrated
improved survival rates among HFOT treated patients
with acute hypoxaemic respiratory failure when com-
pared to patients treated by COT or non-invasive venti-
lation. In patients with acute respiratory failure, the
coordination of breathing-related movements of the rib
cage and abdominal wall is often impaired, leading to re-
spiratory muscle fatigue [27]. This thoraco-abdominal
impairment of synchrony could be improved by HFOT
in patients with mild to moderate respiratory failure
[17]. Moreover, in patients with post-extubation respira-
tory failure, HFOT was as effective as non-invasive ven-
tilation in avoiding reintubation of patients [18, 20].
Limitations of our study might be seen in the relatively
small overall patient number, so that some constraints in
delivering representative data similarly valuable for
greater collectives cannot be fully excluded. In addition,
the short-term regimen reduced to a single one-hour
treatment might render some room for optimization, so
that a third trial under varied conditions is presently in
the planning phase (termed STIT-3 conceived as a long-
term study). Another minor point of limitation might
have been given by the uniform application of the single
low flow rate of 15 L/min, which might possibly be even
further optimised in future studies as currently flow
rates up to 50 L/min are reported to be used.
Overall, the study outcome is considered very promis-
ing leading to the following conclusions. We suggest
HFOT as a novel option of non-invasive treatment pro-
viding an efficacious and safe mode of oxygenation for
COPD patients. Parameters being at least comparable or
even more advantageous compared to COT included the
lower level of oxygen requirement, the significant de-
crease in PaCO2, the conservation of lung functionality,
and a high level of patient satisfaction. A reduction of
oxygen requirement was seen in both patient groups,
with an even more pronounced effect in normocapnic
than in hypercapnic patients. Combined, the findings
demonstrate various aspects of beneficial effects for both
normo- and hypercapnic COPD patients using the novel
HFOT regimen so that larger studies in the near future
might expand on this set of data.
Conclusions
Short-term use of HFOT is safe in normocapnic and hy-
percapnic COPD patients. During HFOT lower oxygen
levels were effective in correcting hypoxemic respiratory
failure and reducing hypercapnia, leading to a reduced
amount of oxygen consumption.
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